Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report
Abstract
This study examines the contraindications of gabapentin and Nucleo C.M.P Forte in metformin-controlled diabetic patients, focusing on their potential to induce hyperglycemia. A case report of a 65-year-old woman with type II diabetes is presented, demonstrating elevated blood glucose levels following the initiation of gabapentin and Nucleo C.M.P Forte. The literature review highlights limited data on gabapentin-induced hyperglycemia, with additional consideration of the potential effects of Nucleo C.M.P Forte. The study suggests modifying insulin therapy in diabetic patients taking gabapentin and calls for further research on this interaction.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.